Barbara E Bierer

List of Publications by Year
in descending order

150 papers	6,369 citations	70961 41 h-index	74018 75 g-index
155 all docs	155 docs citations	155 times ranked	7067 citing authors

#	Article	IF	Citations
1	Using Social Media as a Research Recruitment Tool: Ethical Issues and Recommendations. American Journal of Bioethics, 2017, 17, 3-14.	0.5	306
2	CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature, 1991, 354, 233-235.	13.7	260
3	Immunophilins in protein folding and immunosuppression ¹. FASEB Journal, 1994, 8, 391-400.	0.2	248
4	Eb1 Proteins Regulate Microtubule Dynamics, Cell Polarity, and Chromosome Stability. Journal of Cell Biology, 2000, 149, 761-766.	2.3	243
5	Yeast Bim1p Promotes the G1-specific Dynamics of Microtubules. Journal of Cell Biology, 1999, 145, 993-1007.	2.3	230
6	Suppression of human IL-1Î², IL-2, IFN-Î³, and TNF-Î± production by cigarette smoke extracts. Journal of Allergy and Clinical Immunology, 2000, 106, 280-287.	1.5	227
7	CD28/CTLA-4 and CD80/CD86 families. Immunologic Research, 1999, 19, 1-24.	1.3	167
8	Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Current Opinion in Immunology, 1993, 5, 763-773.	2.4	161
9	Preparing for Responsible Sharing of Clinical Trial Data. New England Journal of Medicine, 2013, 369, 1651-1658.	13.9	155
10	Rapamycin and FK506 binding proteins (immunophilins). Journal of the American Chemical Society, 1991, 113, 1409-1411.	6.6	145
11	Enhancement of T-cell activation by the CD43 molecule whose expression is defective in Wiskottâ€“Aldrich syndrome. Nature, 1991, 350, 706-709.	13.7	145
12	Data Authorship as an Incentive to Data Sharing. New England Journal of Medicine, 2017, 376, 1684-1687.	13.9	139
13	The APC-associated protein EB1 associates with components of the dynactin complex and cytoplasmic dynein intermediate chain. Current Biology, 1999, 9, 425-428.	1.8	138
14	T cell adhesion molecules. FASEB Journal, 1988, 2, 2584-2590.	0.2	137
15	Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood, 1991, 78, 2139-2149.	0.6	131
16	Actin Stabilization by Jasplakinolide Enhances Apoptosis Induced by Cytokine Deprivation. Journal of Biological Chemistry, 1999, 274, 4259-4265.	1.6	125
17	Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood, 1992, 80, 1528-1536.	0.6	120
18	Sharing and reuse of individual participant data from clinical trials: principles and recommendations. BMJ Open, 2017, 7, e018647.	0.8	116

#	Article	IF	Citations
19	A Study of Induced Hyponatremia in the Prevention and Treatment of Sickle-Cell Crisis. New England Journal of Medicine, 1980, 303, 1138-1143.	13.9	114
20	A Framework for Ethical Payment to Research Participants. New England Journal of Medicine, 2018, 378, 766-771.	13.9	111
21	Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. European Journal of Immunology, 1992, 22, 2513-2517.	1.6	99
22	A Global, Neutral Platform for Sharing Trial Data. New England Journal of Medicine, 2016, 374, 2411-2413.	13.9	99
23	T-Lymphocyte Activation: The Biology and Function of CD2 and CD4. Immunological Reviews, 1989, 111, 267-294.	2.8	91
24	Identification of a Physical Interaction between Calcineurin and Nuclear Factor of Activated T Cells (NFATp). Journal of Biological Chemistry, 1996, 271, 1274-1277.	1.6	91
25	Disruptive and avoidable: GDPR challenges to secondary research uses of data. European Journal of Human Genetics, 2020, 28, 697-705.	1.4	91
26	Adhesion receptors in lymphocyte activation. Current Opinion in Immunology, 1994, 6, 385-393.	2.4	86
27	The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. European Journal of Immunology, 1991, 21, 439-445.	1.6	80
28	A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 2001, 28, 187-196.	1.3	76
29	Molecular cloning of a 25-kDa high affinity rapamycin binding protein, FKBP25.. Journal of Biological Chemistry, 1992, 267, 10942-10945.	1.6	76
30	FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. European Journal of Immunology, 1995, 25, 563-571.	1.6	72
31	Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. American Journal of Cardiology, 1983, 51, 904-906.	0.7	69
32	Measurement of Calcineurin Phosphatase Activity in Cell Extracts. Methods, 1996, 9, 146-154.	1.9	67
33	CD80 and CD86 Are Not Equivalent in Their Ability to Induce the Tyrosine Phosphorylation of CD28. Journal of Biological Chemistry, 1999, 274, 3116-3124.	1.6	66
34	Inhibition of actin polymerization enhances commitment to and execution of apoptosis induced by withdrawal of trophic support. Journal of Cellular Biochemistry, 2003, 88, 1066-1076.	1.2	63
35	T cell adhesion, avidity regulation and signaling: a molecular analysis of CD2. Seminars in Immunology, 1993, 5, 249-261.	2.7	61
36	T Cell Signal Transduction and the Role of CD7 in Costimulation. Immunologic Research, 2001, 24, 31-52.	1.3	54

#	Article	IF	Citations
37	Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood, 1994, 84, 3974-3979.	0.6	51
38	Credit data generators for data reuse. Nature, 2019, 570, 30-32.	13.7	51
39	Signaling via LAT (linker for T-cell activation) and Syk/ZAP70 is required for ERK activation and NFAT transcriptional activation following CD2 stimulation. Blood, 2000, 96, 2181-2190.	0.6	45
40	Identification of a Proline-Rich Sequence in the CD2 Cytoplasmic Domain Critical for Regulation of Integrin-Mediated Adhesion and Activation of Phosphoinositide 3-Kinase. Molecular and Cellular Biology, 1998, 18, 5291-5307.	1.1	43
41	Competitive inhibition of calcineurin phosphatase activity by its autoinhibitory domain. Biochemical Journal, 1996, 320, 879-884.	1.7	42
42	Time for NIH to lead on data sharing. Science, 2020, 367, 1308-1309.	6.0	42
43	Upâ€regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is mediated in part by a cAMPâ€responsive element. FASEB Journal, 2002, 16, 354-364.	0.2	41
44	Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation. European Journal of Immunology, 1994, 24, 2664-2671.	1.6	40
45	Identification of Novel Targets of Immunosuppressive Agents by cDNA-based Microarray Analysis. Journal of Biological Chemistry, 2002, 277, 4465-4476.	1.6	38
46	When clinical trials compete: prioritising study recruitment. Journal of Medical Ethics, 2017, 43, 803-809.	1.0	37
47	T Cell Receptors: Adhesion and Signaling. Advances in Cancer Research, 1991, 56, 49-76.	1.9	35
48	Cross-linking CD28 leads to activation of 70-kDa S6 kinase. European Journal of Immunology, 1994, 24, 2364-2368.	1.6	34
49	The complete sequences of plasmids pFNeo and pMH-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines. Gene, 1993, 127, 267-268.	1.0	33
50	Advancing the inclusion of underrepresented women in clinical research. Cell Reports Medicine, 2022, 3, 100553.	3.3	33
51	Association of p59 with the T Lymphocyte Costimulatory Receptor CD2. Journal of Biological Chemistry, 1998, 273, 19914-19921.	1.6	32
52	The SMART IRB platform: A national resource for IRB review for multisite studies. Journal of Clinical and Translational Science, 2019, 3, 129-139.	0.3	32
53	Calcium- and FK506-independent interaction between the immunophilin FKBP51 and calcineurin. Journal of Cellular Biochemistry, 2002, 84, 460-471.	1.2	31
54	Forensic bitemark identification: weak foundations, exaggerated claims. Journal of Law and the Biosciences, 2016, 3, 538-575.	0.8	31

#	Article	IF	Citations
55	IRBs and the Protection-Inclusion Dilemma: Finding a Balance. American Journal of Bioethics, 2023, 23, 75-88.	0.5	31
56	Ethical Challenges in Clinical Research During the COVID-19 Pandemic. Journal of Bioethical Inquiry, 2020, 17, 717-722.	0.9	30
57	Evaluating the frequency of English language requirements in clinical trial eligibility criteria: A systematic analysis using ClinicalTrials.gov. PLoS Medicine, 2021, 18, e1003758.	3.9	30
58	How to fix the GDPR's frustration of global biomedical research. Science, 2020, 370, 40-42.	6.0	29
59	Association of CD2 with tubulin. Evidence for a role of the cytoskeleton in T cell activation.. Journal of Biological Chemistry, 1993, 268, 4979-4988.	1.6	29
60	The effect of desferrithiocin, an oral iron chelator, on T-cell function. Blood, 1990, 76, 2052-2059.	0.6	28
61	Reimagining Health Data Exchange: An Application Programming Interfaceâ€“Enabled Roadmap for India. Journal of Medical Internet Research, 2018, 20, e10725.	2.1	28
62	Data Authorship as an Incentive to Data Sharing. New England Journal of Medicine, 2017, 377, 402-402.	13.9	27
63	The interaction of CD2 with its LFA-3 ligand expressed by autologous erythrocytes results in enhancement of B cell responses. Cellular Immunology, 1988, 116, 308-319.	1.4	25
64	Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation. Biophysical Journal, 1995, 68, 459-470.	0.2	25
65	Expression and function of a CD 5 cDNA in human and murine T cells. European Journal of Immunology, 1988, 18, 747-753.	1.6	24
66	Economic vulnerability and payment for research participation. Clinical Trials, 2020, 17, 264-272.	0.7	24
67	T cell receptor activation of a ribosomal S6 kinase activity. European Journal of Immunology, 1992, 22, 457-462.	1.6	23
68	DISRUPTION OF T CELL DEVELOPMENT AND REPERTOIRE SELECTION BY CALCINEURIN INHIBITION IN VIVO. Transplantation, 1994, 58, 1037-1043.	0.5	23
69	Gelsolin overexpression alters actin dynamics and tyrosine phosphorylation of lipid raft-associated proteins in Jurkat T cells. Molecular Immunology, 2007, 44, 2469-2480.	1.0	21
70	A Descriptive-Multivariate Analysis of Community Knowledge, Confidence, and Trust in COVID-19 Clinical Trials among Healthcare Workers in Uganda. Vaccines, 2021, 9, 253.	2.1	21
71	Fair payment and just benefits to enhance diversity in clinical research. Journal of Clinical and Translational Science, 2021, 5, e159.	0.3	21
72	A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation. Blood, 1989, 73, 1359-1366.	0.6	20

#	Article	IF	Citations
73	Structural organization of the genes encoding human and murine FK506-binding protein (FKBP) 13 and comparison to FKBP1. Gene, 1993, 134, 271-275.	1.0	20
74	Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. Transfusion Science, 1994, 15, 207-220.	0.6	20
75	Differential Phosphorylation of the T Lymphocyte Costimulatory Receptor CD28. Journal of Biological Chemistry, 1996, 271, 13362-13370.	1.6	19
76	T Cell Regulation of p62 (Dok1) Association with Crk-L. Journal of Biological Chemistry, 2001, 276, 45654-45661.	1.6	19
77	Regulation of CXCR4 expression in human T lymphocytes by calcium and calcineurin. Molecular Immunology, 2003, 40, 539-553.	1.0	19
78	Cloning and Characterization of N4WBP5A, an Inducible, Cyclosporine-sensitive, Nedd4-binding Protein in Human T Lymphocytes. Journal of Biological Chemistry, 2003, 278, 34587-34597.	1.6	19
79	Differential chemokine expression profiles in human peripheral blood T lymphocytes: dependence on T-cell coreceptor and calcineurin signaling. Blood, 2003, 101, 216-225.	0.6	19
80	Justice, diversity, and research ethics review. Science, 2021, 371, 1209-1211.	6.0	19
81	Failure of gelsolin overexpression to regulate lymphocyte apoptosis. Blood, 2000, 95, 3483-3488.	0.6	18
82	T-lymphocyte coactivator molecules. Current Opinion in Hematology, 2001, 8, 5-11.	1.2	18
83	A monoclonal antibody to LFA-3, the CD2 ligand, specifically immobilizes major histocompatibility complex proteins. European Journal of Immunology, 1989, 19, 661-665.	1.6	17
84	The Harvard Catalyst Common Reciprocal IRB Reliance Agreement: An Innovative Approach to Multisite IRB Review and Oversight. Clinical and Translational Science, 2015, 8, 57-66.	1.5	17
85	Revised â€˜Common Ruleâ€™ Shapes Protections For Research Participants. Health Affairs, 2017, 36, 784-788.	2.5	17
86	Dental Care in Times of the COVID-19 Pandemic: A Review. Medical Sciences (Basel, Switzerland), 2021, 9, 13.	1.3	17
87	Rapamycin: Biological and therapeutic effects, binding by immunophilins and molecular targets of action. Journal of Computer - Aided Molecular Design, 1994, 2, 163-184.	1.0	15
88	A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation. Blood, 1989, 73, 1359-1366.	0.6	15
89	Confronting Biospecimen Exceptionalism in Proposed Revisions to the Common Rule. Hastings Center Report, 2016, 46, 4-5.	0.7	14
90	Relocation of study participants for rare and ultra-rare disease trials: Ethics and operations. Contemporary Clinical Trials, 2019, 84, 105812.	0.8	13

#	Article	IF	Citations
91	Primed to comply: Individual participant data sharing statements on ClinicalTrials.gov. PLoS ONE, 2020, 15, e0226143.	1.1	13
92	An ethics framework for consolidating and prioritizing COVID-19 clinical trials. Clinical Trials, 2021, 18, 226-233.	0.7	13
93	Cyclosporin A, FK506, and Rapamycin: Binding to Immunophilins and Biological Action1. Chemical Immunology and Allergy, 1994, 59, 128-155.	1.7	10
94	Differences between CEM and Human Peripheral Blood T Lymphocytes in cAMP-Dependent HIV Viral Fusion and CXCR4 Expression. Experimental and Molecular Pathology, 2002, 73, 9-18.	0.9	10
95	Standards for Clinical Research. Circulation, 2016, 133, 823-825.	1.6	10
96	The involvement of the proto-oncogene p120 c-Cbl and ZAP-70 in CD2-mediated T cell activation. International Immunology, 2001, 13, 13-22.	1.8	8
97	Universal Funder Responsibilities That Advance Social Value. American Journal of Bioethics, 2018, 18, 30-32.	0.5	8
98	Leveling the Joint Task Force Core Competencies for Clinical Research Professionals. Therapeutic Innovation and Regulatory Science, 0, , 216847901879929.	0.8	8
99	Implementing expanded COVID-19 testing in Massachusetts community health centers through community partnerships: Protocol for an interrupted time series and stepped wedge study design. Contemporary Clinical Trials, 2022, 118, 106783.	0.8	8
100	The actin cytoskeleton, membrane lipid microdomains, and T cell signal transduction. Advances in Immunology, 2001, 77, 1-43.	1.1	7
101	Biomedical Innovation in Academic Institutions: Mitigating Conflict of Interest. Science Translational Medicine, 2011, 3, 100cm26.	5.8	7
102	Returning aggregate results of clinical trials: Empirical data of patient preferences. Journal of Clinical and Translational Science, 2018, 2, 356-362.	0.3	7
103	Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance. Clinical Trials, 2019, 16, 290-296.	0.7	7
104	Rethinking ethical oversight in the era of the learning health system. Healthcare, 2020, 8, 100462.	0.6	7
105	Aggregating data from COVID-19 trials. Science, 2020, 368, 1198-1199.	6.0	7
106	Issues in the registration of database studies. Journal of Clinical Epidemiology, 2020, 121, 29-31.	2.4	7
107	Testing approaches to sharing trial results with participants: The Show RESPECT cluster randomised, factorial, mixed methods trial. PLoS Medicine, 2021, 18, e1003798.	3.9	7
108	Characterization of Informed Consent Forms Posted on ClinicalTrials.gov. JAMA Network Open, 2021, 4, e2135146.	2.8	7

#	Article	IF	Citations
109	Real-World Evidence: Understanding Sources of Variability Through Empirical Analysis. Value in Health, 2021, 24, 116-117.	0.1	6
110	Integrating Supported Decision-Making into the Clinical Research Process. American Journal of Bioethics, 2021, 21, 32-35.	0.5	6
111	Strategies to optimize inclusion of women in multi-national clinical trials. Contemporary Clinical Trials, 2022, 117, 106770.	0.8	6
112	Research Misconduct Involving Noncompliance in Human Subjects Research Supported by the Public Health Service:Reconciling Separate Regulatory Systems. Hastings Center Report, 2014, 44, S2-S26.	0.7	5
113	Nonexceptionalism, Research Risks, and Social Media: Response to Open Peer Commentaries on â€œUsing Social Media as a Research Recruitment Tool: Ethical Issues and Recommendationsâ€• American Journal of Bioethics, 2017, 17, W1-W3.	0.5	5
114	Protecting Pregnant Women With Substance Use Disorders and Their Neonates Participating in Research. JAMA - Journal of the American Medical Association, 2019, 322, 609.	3.8	5
115	Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood, 1991, 78, 2139-2149.	0.6	5
116	Signaling via LAT (linker for T-cell activation) and Syk/ZAP70 is required for ERK activation and NFAT transcriptional activation following CD2 stimulation. Blood, 2000, 96, 2181-2190.	0.6	5
117	The Education Review Board. Academic Medicine, 2015, 90, 1611-1617.	0.8	4
118	Truth in Advertising: Disclosure of Participant Payment in Research Recruitment Materials. Therapeutic Innovation and Regulatory Science, 2018, 52, 268-274.	0.8	4
119	Social Media as an Ethical Tool for Retention in Clinical Trials. American Journal of Bioethics, 2019, 19, 62-64.	0.5	4
120	Navigating the ethics of remote research data collection. Clinical Trials, 2021, 18, 606-614.	0.7	4
121	Self-assessed Competencies of Clinical Research Professionals and Recommendations for Further Education and Training. Therapeutic Innovation and Regulatory Science, 2022, 56, 607-615.	0.8	4
122	Functional Analysis of Cd2, cd4, and cd8 in t-Cell Activation. Annals of the New York Academy of Sciences, 1988, 532, 199-206.	1.8	3
123	Advancing Health Literacy in Clinical Research: Clear Communications for Every Participant. NAM Perspectives, 2019, 2019, .	1.3	3
124	Incorporating Competencies Related to Project Management into the Joint Taskforce Core Competency Framework for Clinical Research Professionals. Therapeutic Innovation and Regulatory Science, 2022, 56, 206-211.	0.8	3
125	Harvard Catalyst | The Clinical Translational Science Center IND/IDE Consult Service: Providing an IND/IDE Consult Service in a Decentralized Network of Academic Healthcare Centers. Clinical and Translational Science, 2014, 7, 150-155.	1.5	2
126	A Distributed Model: Redefining a Robust Research Subject Advocacy Program at the Harvard Clinical and Translational Science Center. Clinical and Translational Science, 2014, 7, 329-335.	1.5	2

#	Article	IF	Citations
127	Scientific Merit Predicates Ethical Review of Clinical Research. Ethics & Human Research, 2019, 41, 29-32.	0.5	2
128	Demystifying Schrems II for the cross-border transfer of clinical research data. Journal of Law and the Biosciences, 2021, 8, lsab032.	0.8	2
129	Global Clinical Trials: Ethics, Harmonization and Commitments to Transparency. , 0, , .		2
130	Recent advances in immunosuppression. Seminars in Anesthesia, 1995, 14, 85-92.	0.3	1
131	Institutions as an ethical locus of research prioritisation. Journal of Medical Ethics, 2017, 43, 816-818.	1.0	1
132	On Scarcity and the Value of Clinical Trials. American Journal of Bioethics, 2018, 18, 71-73.	0.5	1
133	Facilitating collaborative animal research: The development and implementation of a Master Reciprocal Institutional Agreement for Animal Care and Use. Journal of Clinical and Translational Science, 2020, 4, 96-101.	0.3	1
134	The Decision to Enroll in a Clinical Trial Should Be Unencumbered. American Journal of Bioethics, 2020, 20, 23-25.	0.5	1
135	Committing to the Inclusion of Diverse Populations in Clinical Research. Therapeutic Innovation and Regulatory Science, 2020, 54, 922-924.	0.8	1
136	Applying Civil Rights Law to Clinical Research: Title VIâ€™s Equal Access Mandate. Journal of Law, Medicine and Ethics, 2022, 50, 101-108.	0.4	1
137	Allocation of Opportunities to Participate in Clinical Trials during the Covidâ€19 Pandemic and Other Public Health Emergencies. Hastings Center Report, 2022, 52, 51-58.	0.7	1
138	Acupuncture for hot flashes in hormone receptor-positive breast cancer, a pooled analysis of individual patient data from parallel randomized trials.. Journal of Clinical Oncology, 2022, 40, 12124-12124.	0.8	1
139	Effects of rapamycin on p70 S6-protein kinase. Biomedicine and Pharmacotherapy, 1993, 47, 175.	2.5	0
140	Isolation and Differentiation of Stem and Progenitor Cells. Current Protocols in Immunology, 2012, 98, 22.0.1.	3.6	0
141	Development of a plain-language library of educational resources for research participants. Journal of Clinical and Translational Science, 2018, 2, 27-30.	0.3	0
142	Research Subject Injury Compensation: The Ongoing Search for Fairness, Consistency and Clarity. Journal of Law, Medicine and Ethics, 2019, 47, 748-750.	0.4	0
143	Innovation in biosafety oversight: The Harvard Catalyst Common Reciprocal IBC Reliance Authorization Agreement. Journal of Clinical and Translational Science, 2020, 4, 90-95.	0.3	0
144	Raising standards for global data-sharingâ€”Response. Science, 2021, 371, 134-135.	6.0	0

#	Article	IF	Citations
145	Failure of gelsolin overexpression to regulate lymphocyte apoptosis. Blood, 2000, 95, 3483-3488.	0.6	0
146	The effect of desferrithiocin, an oral iron chelator, on T-cell function. Blood, 1990, 76, 2052-2059.	0.6	0
147	Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood, 1992, 80, 1528-1536.	0.6	0
148	Developing a consensus-driven, plain-language clinical research glossary for study participants and the clinical research community. Journal of Clinical and Translational Science, 0, , 1-20.	0.3	0
149	The Revised and Final Common Rule: An Unfinished Story. IRB: Ethics & Human Research, 2017, 39, 6-10.	0.8	0
150	Global Clinical Trials: Ethics, Harmonization and Commitments to Transparency. , 2015, , .		0